Tubed or tubeless insulin pumps? A retrospective real-world analysis of national French health data
Authors' conclusion
Higher persistence and lower therapy changes among tubeless pump users underscore its sustained benefit for diabetes management.
Study context
- Population
- People with T1D initiating pump therapy, French National Health Data System, 2016–2021
- Participants
- 61,251 pump users
- Exposure
- Tubeless vs tubed insulin pumps
- Outcome
- Treatment persistence
Methodological detailsreal-world, national claims database
- Real-world
- National claims database
Main finding
As reported in the abstract
Treatment persistence (discontinuation)
Tubeless vs TubedEstimate (95% CI)P value
40% lower risk of discontinuation with tubeless
unadjusted HR 0.60(0.58–0.61)
P < 0.0001Treatment persistence (discontinuation)
adjusted HR 0.59(0.57–0.61)
Observational data: associations, not effects.
Further findings
Changes from one therapy to another · 12 months
- Tubeless pumps associated with fewer therapy changes within 12 months
- Treatment changes rose for tubed pump users after tubeless pumps entered the French market
Original publication
Tubed or tubeless insulin pumps? A retrospective real-world analysis of national French health data. BMJ Open Diabetes Res Care. Published 30 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →